H. LUNDBECK A/S

Autres langues H. Lundbeck A/S

Actions

HLUN B

DK0061804770

Marché Fermé - Nasdaq Copenhagen Autres places de cotation 16:59:58 08/05/2024			Varia. 5j.	Varia. 1 janv.
34,58 ^DKK	+1,11 %		+1,59 %	+5,56 %

09/04	H. Lundbeck et Otsuka Pharmaceutical cherchent à obtenir le feu vert de la FDA pour une thérapie combinée contre le SSPT	MT
09/04	Lundbeck et Otsuka soumettent une sNDA pour examen par la FDA de l'association brexpiprazole et sertraline comme traitement potentiel du SSPT	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

H. Lundbeck, Otsuka Pharmaceutical Seek US FDA Nod for PTSD Combination Therapy	09/04
Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD	09/04
Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD	09/04
Lundbeck : Articles of Association	02/04
EU Commission Green-lights Lundbeck, Otsuka's Abilify Maintena as Maintenance Treatment of Schizophrenia	27/03
Abilify Maintena[®] 960 mg (aripiprazole) approved in the EU as the first once-every-two-months long-acting injectable for the maintenance treatment of schizophrenia	27/03
Otsuka Pharmaceutical Europe Ltd. and H. Lundbeck A/S Announces Approval in the EU for the Maintenance Treatment of Schizophrenia	27/03
Lundbeck held its Annual General Meeting on 20 March 2024 at the company's registered office	20/03
H. Lundbeck A/S Announces Management Appointments	20/03
H. Lundbeck A/S Approves Dividend for the Accounting Year 2023	20/03
H. Lundbeck Plans Clinical Development of Migraine Prevention Drug	15/03
Lundbeck's potential first-in-class therapy for migraine prevention enters advanced clinical stage	15/03
H. Lundbeck A/S Announces Potential First-In-Class Therapy for Migraine Prevention Enters Advanced Clinical Stage	15/03
Lundbeck presents encouraging results from the Lu AF82422 trial for Multiple System Atrophy at the international AD/PD 2024 conference on neurodegenerative disorders	05/03
Notice of Annual General Meeting	23/02
H. Lundbeck A/S Proposes Dividend for the Accounting Year 2023	23/02
Lundbeck announces changes to Executive Management	23/02
H. Lundbeck A/S Announces Changes to Executive Management	23/02
Nordic Shares Dropped Tuesday; Lundin Gold Posted Biggest Loss	13/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Dès maintenant, trouvez facilement les meilleurs investissements de demain !

Optimiser mes Profits

fermer